Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02592434 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study Of Tofacitinib In Pediatric JIA Population
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
NCT02592434: Completed Phase 3 study, sponsored by Pfizer.
NCT02592434 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 225 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02592434, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
Study Summary
Evaluate efficacy, safety and tolerability of tofacitinib in pediatric JIA patients.
Primary Outcome
According to PRCSG/PRINTO, disease flare defined as worsening of \>=30 percent(%) in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range of motion accompanied by pain/tenderness), 2)Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a Visual Analog Scale\[VAS\] of 0\[no activity\] to
Interventions
- OTHER placebo
- DRUG CP-690,550 (tofacitinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2016-06-10 |
| Est. Completion | 2019-05-16 |
| Phase | Phase 3 |
What the finished NCT02592434 record still lists
NCT02592434 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02592434 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02592434 about?
NCT02592434 is a clinical study titled "Efficacy Study Of Tofacitinib In Pediatric JIA Population". Evaluate efficacy, safety and tolerability of tofacitinib in pediatric JIA patients.
What is the current status of trial NCT02592434?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2016-06-10. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT02592434?
The interventions under investigation include: placebo (OTHER), CP-690,550 (tofacitinib) (DRUG).
Who is sponsoring clinical trial NCT02592434?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02592434's enrollment target sits among peer trials
225 1311th of 2000 higher than 684 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI